Cancer immunotherapy: the beginning of the end of cancer? - Wikidata - wikimedia - TriplyDB

Cancer immunotherapy: the beginning of the end of cancer?

Cancer immunotherapy: the beginning of the end of cancer?

http://www.wikidata.org/entity/Q26752277

about

Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment Brain metastases from hepatocellular carcinoma: recent advances and future avenues Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma CSPG4: a prototype oncoantigen for translational immunotherapy studies.Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring.Future perspectives in cancer immunotherapy Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario.Cellular immunity augmentation in mainstream oncologic therapy Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Advances in Immunotherapy for Melanoma: A Comprehensive Review.How and when adjuvant treatment should be intensified in stage III colorectal cancers?The safety of nivolumab for the treatment of metastatic melanoma.Immunotherapy of Prostate Cancer: Facts and Hopes.Immunotherapy for head and neck cancer: the future of treatment?The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.Emerging links among Chromosome Instability (CIN), cancer, and aging.Potential applications of nanoparticles in cancer immunotherapy.Cancer Metabolism: Fueling More than Just Growth The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.Cytokines in immunogenic cell death: Applications for cancer immunotherapy.Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.Current status and future prospects for human papillomavirus vaccines.Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.Systemic virotherapy for multiple myeloma.Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies.Immunotherapy of WAP-TNP mice with early stage mammary gland tumors.Circulating tumor DNA for personalized lung cancer monitoring mTOR co-targeting strategies for head and neck cancer therapy The immune response to secondary necrotic cells.Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance.

P2860

Q28071998-4608C04F-D821-46C1-AC49-EA73423A372C Q28073613-52A83B7F-5232-4A3D-8C73-5D8D5D9EF3AF Q33649050-32EDCCDD-D546-46EF-AE67-CFD373CF18A9 Q33741471-BECD1BA6-9229-4999-8D23-EF6725CD9C1D Q33862585-3DDB136B-01AE-4341-9B44-8D05552ED9B0 Q33876878-C94C9F14-0684-4E9F-A695-691D8C72955A Q37147632-1564289B-11FD-4280-8E14-6FBF3C05D443 Q37262696-62BFD152-99DE-4093-A2FD-7EF5A764C1F7 Q37428422-1DF55E37-50B3-4364-9F8E-F079D932E9D0 Q38557424-52F9F311-48EC-4317-AE5C-759F48E04E24 Q38610333-F3DB1A59-934C-44B6-B3D5-145478F514BF Q38636521-049C3C14-3D42-42EE-B616-332C66A621B5 Q38638844-D4AA4C43-514B-42BA-9DA6-9CC3292ECF9D Q38662469-1D725845-4310-421D-9938-B50426FFDB96 Q38664882-04DEAFE6-78F8-4698-BAF3-E2FD95C3ABD6 Q38736238-66A00C8A-651E-48FF-B9DC-621ECB77594A Q38811007-FE227752-E519-4A5E-9D5C-CEA4204F5F35 Q38901871-FF931E30-63FC-417C-B487-EED4E2DCC8BC Q38920328-6BF0FC94-3BA8-4A88-913D-5641115C5FF8 Q38929880-C65F873E-6542-46F6-829D-C6B142245404 Q39015434-3C360CAD-1ADB-408E-8BD3-842536827A68 Q39061395-FEADCC28-2C10-4F63-9DC2-204815C192DC Q39172481-BD67B340-EBAD-4AA1-972B-674A39560B6A Q39233197-B13B5128-9835-4501-8BCD-9D4174EF8A46 Q39280710-87396BFD-B36D-4E0C-966B-837C95F1B9EA Q39397491-2B8CF937-458D-490F-8BEA-5AC37D3009C7 Q39403430-E68866D7-80CD-4B8D-AFC3-5A2801C4C2DB Q39415827-9C2EA338-05FF-4DB3-851C-0F52AFA917B5 Q39446788-FF64D767-A847-48ED-A83B-C279C117A0BF Q40056541-28F4FB40-9227-4C1D-A674-B4F499B26AD9 Q40071126-2FF574D6-79D2-4CD3-8F7D-6E4C7C5A8FAD Q40087770-ECEC78D4-6552-4891-9DAD-77DE9175A8C3 Q41068034-AE6D1D0A-07A3-41EA-8C0A-1405747DB218 Q41514095-AD03392B-3817-4C14-9F8B-D01BACE825A5 Q41684107-B38A16D5-EEB1-4D2C-A194-1D7840958010 Q41924363-F06048BE-F98A-4E25-BBB1-D9E8A98C6846 Q42346466-03610617-E196-425B-9BE6-4CE2641D4F5F Q42363764-64985B22-AFA9-4BCD-99EE-CCAD561C9412 Q42371859-B115A9FA-F5DE-404D-BE9B-FF0B57F4B1F7 Q42378498-8E55FF1A-4219-4BA6-96D6-FE1BCBA8C25D

P2860

Cancer immunotherapy: the beginning of the end of cancer?

http://www.wikidata.org/entity/Q26752277

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Cancer immunotherapy: the beginning of the end of cancer?

@ast

Cancer immunotherapy: the beginning of the end of cancer?

@en

Cancer immunotherapy: the beginning of the end of cancer?

@nl

type

label

Cancer immunotherapy: the beginning of the end of cancer?

@ast

Cancer immunotherapy: the beginning of the end of cancer?

@en

Cancer immunotherapy: the beginning of the end of cancer?

@nl

prefLabel

Cancer immunotherapy: the beginning of the end of cancer?

@ast

Cancer immunotherapy: the beginning of the end of cancer?

@en

Cancer immunotherapy: the beginning of the end of cancer?

@nl

P1433

Q26752277-387F73FB-9CF6-44A0-91E7-A9783B911DF3

P1476

Q26752277-1F1CE8E0-565D-4362-9135-19CDA84F3074

P2093

Q26752277-28F7F195-C9F1-4F94-9C7B-E0AAD00EDBA7

P275

Q26752277-F76F3FFD-31A2-4F67-B0CD-61983CFBC15E

P2860

Q26752277-065F0C39-D8F8-4D3E-B625-A4769AD83700

Q26752277-0C261385-0FDB-4530-B18F-115DE07CA39B

Q26752277-0C72F564-E4BD-4010-8AEA-57ACC14467C7

Q26752277-0C8E9D7D-49A6-47F6-9D50-E6ACDBDD5573

Q26752277-0EBCB3C1-11A8-49E5-B84A-6998E54DBD6B

Q26752277-101954F8-ECAF-4FF7-ADD5-1513D8EB6A96

Q26752277-10335AD8-D6BB-40F9-8B14-54960161A01E

Q26752277-12B3912E-1A83-4FD6-9D60-E237938C0EE2

Q26752277-13659C50-7BBE-4729-9640-ECC037CD3332

Q26752277-1530F78A-A651-4D8D-9F48-96E47A3D0FE7

P2888

Q26752277-029CDED6-33B8-49E9-9BDE-69B9ED6940CA

P304

Q26752277-BD6F1FF3-F509-4F53-A734-80DC3D0D2245

P31

Q26752277-BCABD5A2-8297-4EF9-82AA-75F08AFF7791

Q26752277-FDAF89B3-E34C-46A0-8BD2-DAF0D0A6C379

P3181

Q26752277-5F41CB3A-B0D7-47A7-954E-647F381BB848

P356

Q26752277-2885CF6F-2F4C-493C-9CFD-2E971D025C78

P407

Q26752277-7D766DCA-0DEC-4A01-B799-DDA683BCC7FD

P433

Q26752277-CE75761E-A1E2-4729-B9C1-C0234520A3CD

P478

Q26752277-0A8DEC32-2AB5-4D7E-BCB7-9D95AA7C3157

P50

Q26752277-3728C3CE-AE05-4706-940A-50CEFC9F440C

Q26752277-A3665D13-717E-4FA4-B993-01388D3F8A1F

P5008

Q26752277-FDF1A516-EC17-4F86-AB51-762696139CFB

P577

Q26752277-701F3ED2-CB4A-40C7-9A7F-C7266D5BF758

P6179

Q26752277-FAF12DA8-D31C-4129-BBE0-A2E2960FA9F0

P698

Q26752277-2866EEFB-2A21-483D-8A01-94A8DFAEE2D0

P921

Q26752277-024FAC16-CCD3-4C38-AA02-FF61F096CC50

Q26752277-5B0345A2-0E1D-4F05-A12F-18AA59411256

Q26752277-858302EB-88C7-4427-ADB8-F55F51529357

Q26752277-8A873C9C-5742-422A-8BA5-78AA93439004

Q26752277-A327378D-533B-429F-B560-8D8533CCD54F

Q26752277-B7226A2A-9FEE-4D63-AA5B-CF67FFC26867

Q26752277-D28791CE-B53C-4CC1-B08E-943C42B77C1F

P932

Q26752277-9F8B3F25-4914-49C2-B55C-5B75E7FCC453

P3181

P356

S12916-016-0623-5

P1433

P1476

Cancer immunotherapy: the beginning of the end of cancer?

@en

P2093

Sofia Farkona

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Hallmarks of Cancer: The Next Generation

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

LAG-3, a novel lymphocyte activation gene closely related to CD4

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Cancer immunotherapy: moving beyond current vaccines

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

P2888

s12916-016-0623-5

P304

73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1831285

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12916-016-0623-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Eleftherios P. Diamandis

P5008

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017735955

http://www.w3.org/2001/XMLSchema#string

P698

27151159

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

monoclonal antibody

membrane proteins

P932

4858828

http://www.w3.org/2001/XMLSchema#string